Type 1 primary hyperoxaluria is a genetic disease caused by deficiency or absence of liver-specific alanine:glyoxylate aminotransferase, which leads to overproduction of endogenous oxalate.

VARIOUS measures have been proposed to reduce the endogenous production of oxalic acid in patients with primary hyperoxaluria; these include the oral administration of sodium benzoate, 1 ...

1990 Reusz and his colleagues reported that hyperoxaluria during phosphate supplementation in XLH might contribute to the development of nephrocalcinosis in this discorder. We analysed 18 random ...

PH1 is a rare condition with potentially devastating consequences, especially when onset occurs early in life. Are you up to date with recent developments? Take this quiz to find out. At the end ...

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran ...

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

Then, on May 1, 2024, Metagenomi announced that it and Moderna, Inc. had "mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1)," and that the "rights to develop the ...